Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).

Objective: To evaluate the efficacy and safety of ibrexafungerp versus placebo for acute vulvovaginal candidiasis (VVC) treatment.

Design: Global phase 3, randomised, placebo-controlled superiority study.

Setting: Study sites in the USA (n = 19) and Bulgaria (n = 18).